Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH)

Urological Clinic, Department of Surgical, Oncological and Gastroenterological Sciences, School of Medicine and Surgery, University of Padova, 35124 Padova, Italy

Author to whom correspondence should be addressed.

Int. J. Mol. Sci. 2020, 21(23), 9178; https://doi.org/10.3390/ijms21239178

Received: 2 November 2020 / Revised: 26 November 2020 / Accepted: 30 November 2020 / Published: 2 December 2020

(This article belongs to the Special Issue Nutraceuticals in Chronic Diseases)

View Full-Text Download PDF

Browse Figures

Review Reports Citation Export

Abstract

Benign prostatic hyperplasia (BPH) is an age-related chronic disorder, characterized by the hyperproliferation of prostatic epithelial and stromal cells, which drives prostate enlargement. Since BPH aetiology and progression have been associated with the persistence of an inflammatory stimulus, induced both by Nuclear Factor-kappa B (NF-κB) activation and reactive oxygen species (ROS) production, the inhibition of these pathways could result in a good tool for its clinical treatment. This study aimed to evaluate the antioxidant and anti-inflammatory activity of a combined formulation of Serenoa repens and Urtica dioica (SR/UD) in an in vitro human model of BPH. The results confirmed both the antioxidant and the anti-inflammatory effects of SR/UD. In fact, SR/UD simultaneously reduced ROS production, NF-κB translocation inside the nucleus, and, consequently, interleukin 6 (IL-6) and interleukin 8 (IL-8) production. Furthermore, the effect of SR/UD was also tested in a human androgen-independent prostate cell model, PC3. SR/UD did not show any significant antioxidant and anti-inflammatory effect, but was able to reduce NF-κB translocation. Taken together, these results suggested a promising role of SR/UD in BPH and BPH-linked disorder prevention. View Full-Text

Keywords: BPH; inflammation; oxidative stress; Serenoa repens; Urtica dioica

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share and Cite

MDPI and ACS Style

Saponaro, M.; Giacomini, I.; Morandin, G.; Cocetta, V.; Ragazzi, E.; Orso, G.; Carnevali, I.; Berretta, M.; Mancini, M.; Pagano, F.; Montopoli, M. Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH). Int. J. Mol. Sci. 2020, 21, 9178. https://doi.org/10.3390/ijms21239178

AMA Style

Saponaro M, Giacomini I, Morandin G, Cocetta V, Ragazzi E, Orso G, Carnevali I, Berretta M, Mancini M, Pagano F, Montopoli M. Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH). International Journal of Molecular Sciences. 2020; 21(23):9178. https://doi.org/10.3390/ijms21239178

Chicago/Turabian Style

Saponaro, Miriam, Isabella Giacomini, Giulia Morandin, Veronica Cocetta, Eugenio Ragazzi, Genny Orso, Ilaria Carnevali, Massimiliano Berretta, Mariangela Mancini, Francesco Pagano, and Monica Montopoli. 2020. "Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH)" International Journal of Molecular Sciences 21, no. 23: 9178. https://doi.org/10.3390/ijms21239178

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH)

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI